Smith Salley Wealth Management Acquires 713 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Smith Salley Wealth Management increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 6.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 11,106 shares of the medical research company’s stock after buying an additional 713 shares during the period. Smith Salley Wealth Management’s holdings in IQVIA were worth $2,183,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Nordea Investment Management AB raised its holdings in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Simplify Asset Management Inc. lifted its position in IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the period. Versor Investments LP acquired a new stake in IQVIA during the third quarter worth about $1,328,000. JPMorgan Chase & Co. increased its holdings in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after buying an additional 583,396 shares during the period. Finally, CIBC Asset Management Inc raised its position in shares of IQVIA by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock valued at $62,501,000 after buying an additional 8,490 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Down 0.2 %

Shares of IQV stock opened at $197.25 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The stock has a 50-day moving average of $200.09 and a 200-day moving average of $221.29. The stock has a market cap of $35.80 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 2.09 and a beta of 1.48.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on IQV shares. Bank of America decreased their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Stephens initiated coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Barclays reduced their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. TD Cowen lowered their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Evercore ISI reduced their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $255.82.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.